Janssen to start phase III trial of daratumumab in multiple myeloma in Q4 2014 Genmab partner Janssen Biotech (Janssen) is planning to start a new phase III trial of daratumumab for the treatment of patients with multiple myeloma during the fourth quarter of 2014. 

READ FULL ARTICLE Curated publisher From Pharmaceutical Business Review